Literature DB >> 29569621

Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.

Héctor F Escobar-Morreale1,2,3,4.   

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders in premenopausal women. Heterogeneous by nature, PCOS is defined by a combination of signs and symptoms of androgen excess and ovarian dysfunction in the absence of other specific diagnoses. The aetiology of this syndrome remains largely unknown, but mounting evidence suggests that PCOS might be a complex multigenic disorder with strong epigenetic and environmental influences, including diet and lifestyle factors. PCOS is frequently associated with abdominal adiposity, insulin resistance, obesity, metabolic disorders and cardiovascular risk factors. The diagnosis and treatment of PCOS are not complicated, requiring only the judicious application of a few well-standardized diagnostic methods and appropriate therapeutic approaches addressing hyperandrogenism, the consequences of ovarian dysfunction and the associated metabolic disorders. This article aims to provide a balanced review of the latest advances and current limitations in our knowledge about PCOS while also providing a few clear and simple principles, based on current evidence-based clinical guidelines, for the proper diagnosis and long-term clinical management of women with PCOS.

Entities:  

Mesh:

Year:  2018        PMID: 29569621     DOI: 10.1038/nrendo.2018.24

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  181 in total

1.  Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.

Authors:  Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2006-01-17       Impact factor: 5.958

2.  Polycystic ovary syndrome: perceptions and attitudes of women and primary health care physicians on features of PCOS and renaming the syndrome.

Authors:  Helena Teede; Melanie Gibson-Helm; Robert J Norman; Jacqueline Boyle
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

3.  Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.

Authors:  Thomas M Barber; John A H Wass; Mark I McCarthy; Stephen Franks
Journal:  Clin Endocrinol (Oxf)       Date:  2007-04       Impact factor: 3.478

Review 4.  The levonorgestrel intrauterine system: more than a contraceptive.

Authors:  K Andersson
Journal:  Eur J Contracept Reprod Health Care       Date:  2001-01       Impact factor: 1.848

Review 5.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

Review 6.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

Review 7.  Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective.

Authors:  Carla Musso; Elaine Cochran; Stephanie Ann Moran; Monica C Skarulis; Elif Arioglu Oral; Simeon Taylor; Phillip Gorden
Journal:  Medicine (Baltimore)       Date:  2004-07       Impact factor: 1.889

8.  Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome.

Authors:  Tevfik Sabuncu; Muge Harma; Mehmet Harma; Yasar Nazligul; Feryal Kilic
Journal:  Fertil Steril       Date:  2003-11       Impact factor: 7.329

Review 9.  Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response.

Authors:  M Simoni; C B Tempfer; B Destenaves; B C J M Fauser
Journal:  Hum Reprod Update       Date:  2008-07-04       Impact factor: 15.610

10.  Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations.

Authors:  M Geoffrey Hayes; Margrit Urbanek; David A Ehrmann; Loren L Armstrong; Ji Young Lee; Ryan Sisk; Tugce Karaderi; Thomas M Barber; Mark I McCarthy; Stephen Franks; Cecilia M Lindgren; Corrine K Welt; Evanthia Diamanti-Kandarakis; Dimitrios Panidis; Mark O Goodarzi; Ricardo Azziz; Yi Zhang; Roland G James; Michael Olivier; Ahmed H Kissebah; Elisabet Stener-Victorin; Richard S Legro; Andrea Dunaif
Journal:  Nat Commun       Date:  2015-08-18       Impact factor: 14.919

View more
  264 in total

Review 1.  Chronic low-grade inflammation in polycystic ovary syndrome: is there a (patho)-physiological role for interleukin-1?

Authors:  Milica Popovic; Gideon Sartorius; Mirjam Christ-Crain
Journal:  Semin Immunopathol       Date:  2019-05-28       Impact factor: 9.623

2.  Response to "Reproductive Function Abnormalities and Bariatric Surgery: is a Matter of Time?"

Authors:  Jacob Christ; Tommaso Falcone
Journal:  Obes Surg       Date:  2019-01       Impact factor: 4.129

Review 3.  Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.

Authors:  David H Abbott; Daniel A Dumesic; Jon E Levine
Journal:  Expert Rev Endocrinol Metab       Date:  2019-02-15

Review 4.  Emerging Roles of Anti-Müllerian Hormone in Hypothalamic-Pituitary Function.

Authors:  Anne-Laure Barbotin; Maëliss Peigné; Samuel Andrew Malone; Paolo Giacobini
Journal:  Neuroendocrinology       Date:  2019-07-05       Impact factor: 4.914

5.  Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome.

Authors:  Anna Krentowska; Agnieszka Łebkowska; Małgorzata Jacewicz-Święcka; Justyna Hryniewicka; Monika Leśniewska; Agnieszka Adamska; Irina Kowalska
Journal:  Endocrine       Date:  2021-01-13       Impact factor: 3.633

Review 6.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

7.  DNA methylation in promoter regions of genes involved in the reproductive and metabolic function of children born to women with PCOS.

Authors:  Bárbara Echiburú; Fermín Milagro; Nicolás Crisosto; Francisco Pérez-Bravo; Cristian Flores; Ana Arpón; Francisca Salas-Pérez; Sergio E Recabarren; Teresa Sir-Petermann; Manuel Maliqueo
Journal:  Epigenetics       Date:  2020-04-20       Impact factor: 4.528

8.  Novel PGK1 determines SKP2-dependent AR stability and reprograms granular cell glucose metabolism facilitating ovulation dysfunction.

Authors:  Xia Liu; Changfa Sun; Kexin Zou; Cheng Li; Xiaojun Chen; Hangchao Gu; Zhiyang Zhou; Zuwei Yang; Yaoyao Tu; Ningxin Qin; Yiran Zhao; Yimei Wu; Yicong Meng; Guolian Ding; Xinmei Liu; Jianzhong Sheng; Chuanjin Yu; Hefeng Huang
Journal:  EBioMedicine       Date:  2020-10-21       Impact factor: 8.143

Review 9.  Update on adrenarche.

Authors:  Selma Feldman Witchel; Bianca Pinto; Anne Claire Burghard; Sharon E Oberfield
Journal:  Curr Opin Pediatr       Date:  2020-08       Impact factor: 2.856

Review 10.  In utero Androgen Excess: A Developmental Commonality Preceding Polycystic Ovary Syndrome?

Authors:  David H Abbott; Marissa Kraynak; Daniel A Dumesic; Jon E Levine
Journal:  Front Horm Res       Date:  2019-09-09       Impact factor: 2.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.